Merck touts a confirmatory Keytruda win for liver cancer as 'dangling' accelerated approval saga marches on

Accelerated approval for Merck’s Keytruda in a common form of liver cancer looked tenuous after a confirmatory study whiffed on two survival measures. But after ODAC recommended to keep the drug on the market back in April, the pharma giant said Monday another trial has brought better tidings.